InsidersTradesSigma
Follow the BioGene Therapeutics Inc. stock price and the full insider trade history of the company, a publicly traded company based in Canada. Shares are listed on the CA market, under the oversight of SEDI. Market capitalisation: €31.3bn. The latest transaction was reported on 19 July 2026 (00 - Opening Balance-Initial SEDI Report). Among the most active insiders: Moeller, Michael. Every trade is accessible without an account.
Analysts rate BioGene Therapeutics Inc. Strong Buy (bullish), based on 16 analysts. Average price target: HK$41.02.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
BioGene Therapeutics Inc. is a company focused on developing gene therapies to treat genetic diseases. It is listed on the XTSE.